Our client was looking to build a capability in radionucleotide imaging and was seeking merger and acquisition opportunities in Europe and the US. One target company was developing a new Rubidium-82 radionuclide generator, which is used for cardiac imaging.
We were commissioned to conduct technical, regulatory and commercial due diligence on the company. As part of the commercial due diligence, we interviewed 45 cardiologists across the USA and Europe, building a picture of the commercial attractiveness and reimbursement prospects of the product that was in development.
We identified major flaws in the company’s execution plan and commercial projections, fundamentally undermining the business case for our client’s investment.
Alacrita's due diligence consultants have been a trusted source of pharma and biotech DD for over 15 years, underpinned by our ability to ensure each due diligence exercise is supported by individuals with the precise industry expertise required to be thorough, complete and accurate.